Physician profile
Richard L Armour
NPI 1366488215
$14,073.68
in general payments reported to CMS, 2019-2025
62 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,872 · 2020: $1,838 · 2021: $2,563 · 2022: $2,397 · 2023: $2,297 · 2024: $1,504 · 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,265 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,264.69 |
| Education | $139.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,363.86 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,039.70 | 2019-2025 | |
| Novo Nordisk INC | $921.24 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $808.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $792.31 | 2019-2025 | Jardiance |
| Amgen INC. | $648.54 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $646.51 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $583.10 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $534.07 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $498.46 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $491.74 | 2019-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $418.00 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $411.43 | 2019-2023 | Trintellix |
| Sumitomo Pharma America, INC. | $384.58 | 2023-2025 | Gemtesa, Myfembree |
| Kowa Pharmaceuticals America, INC. | $373.95 | 2020-2023 | Livalo, Seglentis |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Armour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.